Let’s play a game: do you think more people have died of the
Ebola virus in West Africa, or an everyday infection? Although Ebola may be a tempting answer, bacterial and fungal infections have become
exceedingly deadly over the past few years. According to the Centers for
Disease Control, fewer than 9,000
people have died of Ebola in the past year, while over
2 million people in the U.S. alone have developed serious infections and at
least 23,000
of those people have died as a direct result. Many
others have died from other medical conditions that were further complicated by
infections.
These alarming statistics seem to magnify the increasing
trend of antibiotic resistance.
Antibiotic resistance occurs when microbes – or bacteria,
viruses, fungi and parasites – acquire a genetic mutation that prevents drugs
from affectively killing the microbes. Over time, these robust microbes
transfer their antibiotic resistant genes to nearby microbes, which
continuously facilitates the spread of antibiotic resistance.
The spread of antibiotic resistance limits the effectiveness
of drugs and has caused a massive public health scare. This has prompted
scientists to consistently discover and introduce new compounds. During the early
era of drug discovery, scientists traditionally found most antibiotics by
cultivating soil bacteria. Despite many years of success, overmining soil
bacteria has resulted in the collapse of drug discovery from natural
environments.
Scientists stopped discovering useful soil bacteria decades
ago because they did not have the proper technology to examine the bacteria in situ (within their natural
environment). This limited their search to bacterial species that could be
readily cultured, or grow under laboratory conditions. Uncultured bacteria were
out of the picture.
However, uncultured bacteria make up approximately 99% of
all bacterial species in natural environments. This enticing statistic has
urged scientists to come up with new technologies to examine uncultured
bacteria. According to the K. Lewis of Northeastern University, this technology
is possible and already being put to use. Lewis
and his colleagues developed a method of growing uncultured microbes within
their natural environment. With this new method, they discovered a new
antibiotic they termed teixobactin that kills pathogens without any known,
detectable resistance. Lewis and his team suggest that it will take over 30
years for bacteria to become resistant to teixobactin.
Although that news is exciting within itself, the research
community is even more excited about the technique used to examine teixobactin:
the iChip. In 2010, the iChip was first developed by D. Nichols of
Northeastern University and then borrowed by Lewis for experimentation
purposes. Nichols and his team built off of their earlier method of in situ cultivation, where microbes
thrived inside diffusion chambers containing naturally occurring growth
factors. They utilized this design and complied the miniature diffusion
chambers onto an isolation chip – or iChip, for short.
iChip
configuration. http://www.nature.com/nature/journal/v517/n7535/full/nature14098.html
In order to successfully grow the soil microbes, Nichols
assembled a flat plate containing uniform holes (a) and then dipped the plate
into a suspension of mixed cells. Each hole captured a single cell (b), which
was then sealed with semi-permeable membranes (c). The iChips were then
returned to their natural environments, and this case waterlogged soil. This
process allowed microbes to easily absorb nutrients and growth factors from
their natural environments. After 2 weeks, Nichols and his team identified the
microbes using genetic sequencing and compared their results to microbial
growth on petri dishes.
iChip in the field - Slava Epstien/ Northeastern University
They discovered that the microbes within the iChip grew approximately 30% larger colonies compared to the petri dishes. The iChip also exhibited 94-97% genetic similarities to known bacterial species, which means there is a 3-6% chance of novel microbial discovery. In comparison, the soil bacteria cultivated on petri dishes resembled 97-100% identity with previously cultivated species. Although these numbers may seem insignificant, the provide big hope to the science community in conquering antibiotic resistance.
Microbe
colonies from iChip under microscope
- http://aem.asm.org/content/76/8/2445.full#aff-1
The ability of the iChip to cultivate novel microbes is
exceedingly desirable to scientists because new antibiotics are less likely to
experience a rapid rise in resistance (as seen in Lewis teixobactin). This
spectacular diversity of microbes will slow down – and hopefully stop – antibiotic
resistance right in its tracks.
1) Lewis, Kim (2012). Antibiotics: Recover the lost art of drug
discovery. Nature. 485, 439-440.
2) Ling, L. L. (2015). A new antibiotic
kills pathogens without detectable resistance. Nature. 485, 455-459.
3)
Nichols, D. (2010). Use of Ichip for High-Throughput In
SituCultivation of “Uncultivable” Microbial Species. Applied and Environmental Microbiology. 76(8),
2445-3450.
This was a really interesting topic, because understanding as many strains of bacteria as possible is the key to antibiotic resistance (and other medical innovations that utilize the properties of bacteria). One thing I am wondering about is if scientists can use the same principles of the iChip (in situ), or maybe the iChip itself, to the human microbiota that are hard to be cultured/studied outside of the human body because they are anaerobic.
ReplyDeleteI found this post to be very exciting and extremely relevant. We're now moving into what some people are calling the "Age of Antibiotic Resistance", which is a very serious public health concern. Being able to grow bacteria within these iChips may become something we rely on in the future, as overexploiting of biotic in both the human and agriculture/animal farming spheres increases exponentially. Developments like this in combination of reduced antibiotic industrial transfer are the only hope for antibiotic treatments in this new era.
ReplyDeleteI found this article to be incredibly relevant- antibiotic resistance is a major issue in healthcare today and will continue to be a large problem unless it is addressed. Seeing research like this is heartening.
ReplyDeleteThis is so interesting! I was just wondering why they are so confident that these new antibiotics are less likely to rapidly experience a rise in resistance?
ReplyDeleteI hear so much about antibiotic resistance nowadays that it's refreshing to see something that will, at least, stave off problems of antibiotic resistance for a while. Also, I wasn't aware of how important that soil bacteria are for drug discovery. I assumed most of it was done in labs nowadays. Hopefully in the future, more attention will be paid towards making technologies like this to help slow down (or perhaps even reverse) the trend of antibiotic resistance.
ReplyDeleteI recetnly pusblished a post on this same research and am very impressed with your information about the iChip wich is added information to me. The new drug,Teixobactin, that Lewis discovered has not yet had any resistance and hopefully more discoveries are on the rise!
ReplyDelete